| Primary |
| Drug Use For Unknown Indication |
17.0% |
| Ill-defined Disorder |
11.6% |
| Tooth Infection |
8.8% |
| Tooth Abscess |
7.5% |
| Product Used For Unknown Indication |
5.4% |
| Infection |
4.8% |
| Osteomyelitis |
4.8% |
| Osteitis |
4.1% |
| Renal Hypertension |
4.1% |
| Acne |
3.4% |
| Adverse Drug Reaction |
3.4% |
| Toothache |
3.4% |
| Antibiotic Therapy |
2.7% |
| Cerebral Toxoplasmosis |
2.7% |
| Endocarditis Prophylaxis |
2.7% |
| Hiv Infection |
2.7% |
| Hypertension |
2.7% |
| Neoplasm |
2.7% |
| Pustular Psoriasis |
2.7% |
| Respiratory Tract Infection |
2.7% |
|
| Acute Generalised Exanthematous Pustulosis |
7.6% |
| Laryngeal Oedema |
7.6% |
| Rash |
7.6% |
| Renal Failure Acute |
7.6% |
| Drug Interaction |
6.1% |
| International Normalised Ratio Increased |
6.1% |
| Vomiting |
6.1% |
| Clostridial Infection |
4.5% |
| Influenza Like Illness |
4.5% |
| Movement Disorder |
4.5% |
| Restless Legs Syndrome |
4.5% |
| Tracheitis |
4.5% |
| Unintended Pregnancy |
4.5% |
| Urticaria |
4.5% |
| Vaginal Infection |
4.5% |
| Acute Febrile Neutrophilic Dermatosis |
3.0% |
| Clostridium Difficile Colitis |
3.0% |
| Diarrhoea |
3.0% |
| Drug Eruption |
3.0% |
| Dyskinesia |
3.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
11.9% |
| Clostridium Difficile Infection |
10.9% |
| Infection |
10.4% |
| Tooth Infection |
10.4% |
| Hiv Infection |
6.7% |
| Hypertension |
6.7% |
| Product Used For Unknown Indication |
6.7% |
| C-reactive Protein Increased |
4.1% |
| Nasopharyngitis |
3.6% |
| Ill-defined Disorder |
3.1% |
| Lupus Nephritis |
3.1% |
| Toxoplasmosis |
3.1% |
| Urticaria |
3.1% |
| Pain |
2.6% |
| Pyrexia |
2.6% |
| Sepsis |
2.6% |
| Aneurysm Ruptured |
2.1% |
| Anxiety |
2.1% |
| Diabetic Foot |
2.1% |
| Staphylococcal Sepsis |
2.1% |
|
| Weight Decreased |
16.7% |
| Toxic Epidermal Necrolysis |
11.9% |
| Jaundice |
7.1% |
| Rash |
7.1% |
| Henoch-schonlein Purpura |
4.8% |
| Hepatitis Cholestatic |
4.8% |
| Movement Disorder |
4.8% |
| Prothrombin Time Prolonged |
4.8% |
| Skin Ulcer |
4.8% |
| Tooth Abscess |
4.8% |
| Urinary Tract Infection |
4.8% |
| Vision Blurred |
4.8% |
| Analgesic Drug Level Increased |
2.4% |
| Autoimmune Thrombocytopenia |
2.4% |
| Caesarean Section |
2.4% |
| Cholestasis |
2.4% |
| Death |
2.4% |
| Drug Exposure During Pregnancy |
2.4% |
| Drug Interaction |
2.4% |
| Eye Swelling |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
23.0% |
| Prophylaxis |
14.7% |
| Product Used For Unknown Indication |
10.2% |
| Pain |
7.7% |
| Hiv Infection |
7.1% |
| Pneumocystis Jiroveci Pneumonia |
7.0% |
| Rheumatoid Arthritis |
4.1% |
| Pulmonary Tuberculosis |
3.2% |
| Diabetes Mellitus |
2.9% |
| Depression |
2.8% |
| Metastases To Bone |
2.8% |
| Hypertension |
2.3% |
| Adverse Event |
1.9% |
| Cytomegalovirus Oesophagitis |
1.9% |
| Non-small Cell Lung Cancer |
1.8% |
| Colitis Ulcerative |
1.5% |
| Acne |
1.3% |
| Arthritis |
1.3% |
| Contraception |
1.3% |
| Polyneuropathy |
1.3% |
|
| Weight Decreased |
23.8% |
| Tooth Extraction |
14.8% |
| Vitreous Floaters |
7.4% |
| Vomiting |
6.6% |
| Rash |
4.9% |
| Pain |
4.1% |
| Urinary Retention |
4.1% |
| White Blood Cell Count Decreased |
4.1% |
| Pyrexia |
3.3% |
| Renal Failure Acute |
3.3% |
| Sepsis |
3.3% |
| Bursitis |
2.5% |
| Colitis |
2.5% |
| Large Intestine Perforation |
2.5% |
| Non-small Cell Lung Cancer |
2.5% |
| Respiratory Failure |
2.5% |
| Swelling |
2.5% |
| Weight Increased |
2.5% |
| Drug Level Decreased |
1.6% |
| Dyspnoea |
1.6% |
|
| Interacting |
| Renal Cell Carcinoma |
30.0% |
| Scar |
30.0% |
| Metastases To Spine |
10.0% |
| Smoking Cessation Therapy |
10.0% |
| Tooth Abscess |
10.0% |
| Toothache |
10.0% |
|
| Thrombocytopenia |
50.0% |
| Hypertension |
25.0% |
| Toothache |
25.0% |
|
